title: The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
authors.affiliation: Dana Hu-Lowe, Oncology Translational Research, Pfizer Inc, San Diego, CA 92121, USA. dana.hu-lowe@pfizer.com
authors.forename: Dana
authors.initials: D
authors.lastname: Hu-Lowe
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Brega
authors.forename: Shem
authors.initials: S
authors.lastname: Patyna
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D009025:Morpholines / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D009025:Morpholines; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases